<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35159383</PMID><DateCompleted><Year>2022</Year><Month>04</Month><Day>08</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>08</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2073-4409</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><Issue>3</Issue><PubDate><Year>2022</Year><Month>Feb</Month><Day>07</Day></PubDate></JournalIssue><Title>Cells</Title><ISOAbbreviation>Cells</ISOAbbreviation></Journal><ArticleTitle>The Biogenesis of miRNAs and Their Role in the Development of Amyotrophic Lateral Sclerosis.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">572</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/cells11030572</ELocationID><Abstract><AbstractText>Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease that affects upper and lower motor neurons. As there is no effective treatment for ALS, it is particularly important to screen key gene therapy targets. The identifications of microRNAs (miRNAs) have completely changed the traditional view of gene regulation. miRNAs are small noncoding single-stranded RNA molecules involved in the regulation of post-transcriptional gene expression. Recent advances also indicate that miRNAs are biomarkers in many diseases, including neurodegenerative diseases. In this review, we summarize recent advances regarding the mechanisms underlying the role of miRNAs in ALS pathogenesis and its application to gene therapy for ALS. The potential of miRNAs to target diverse pathways opens a new avenue for ALS therapy.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Jinmeng</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-6041-2723</Identifier><AffiliationInfo><Affiliation>Laboratory of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Weifang Medical University, Weifang 261053, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neurologic Disorders and Regenerative Repair Laboratory, Weifang Medical University, Weifang 261053, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Fenghua</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Neurologic Disorders and Regenerative Repair Laboratory, Weifang Medical University, Weifang 261053, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology, School of Basic Medical Sciences, Weifang Medical University, Weifang 261053, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guan</LastName><ForeName>Yingjun</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Neurologic Disorders and Regenerative Repair Laboratory, Weifang Medical University, Weifang 261053, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Histology and Embryology, School of Basic Medical Sciences, Weifang Medical University, Weifang 261053, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meng</LastName><ForeName>Fandi</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Histology and Embryology, School of Basic Medical Sciences, Weifang Medical University, Weifang 261053, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Zhenhan</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Histology and Embryology, School of Basic Medical Sciences, Weifang Medical University, Weifang 261053, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Su</LastName><ForeName>Qi</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Department of Histology and Embryology, School of Basic Medical Sciences, Weifang Medical University, Weifang 261053, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bao</LastName><ForeName>Weiwei</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Histology and Embryology, School of Basic Medical Sciences, Weifang Medical University, Weifang 261053, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Xuemei</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Histology and Embryology, School of Basic Medical Sciences, Weifang Medical University, Weifang 261053, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Jiantao</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Histology and Embryology, School of Basic Medical Sciences, Weifang Medical University, Weifang 261053, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huo</LastName><ForeName>Zijun</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Histology and Embryology, School of Basic Medical Sciences, Weifang Medical University, Weifang 261053, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Lingyun</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Neurologic Disorders and Regenerative Repair Laboratory, Weifang Medical University, Weifang 261053, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Shuanhu</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0003-4745-5347</Identifier><AffiliationInfo><Affiliation>Department of Orthopedic Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Yanchun</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0003-4740-9228</Identifier><AffiliationInfo><Affiliation>Neurologic Disorders and Regenerative Repair Laboratory, Weifang Medical University, Weifang 261053, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Histology and Embryology, School of Basic Medical Sciences, Weifang Medical University, Weifang 261053, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Xin</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Neurosurgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>81871006</GrantID><Agency>National Natural Science Foundation of China</Agency><Country/></Grant><Grant><GrantID>ZR2020MH150 and ZR2020MH149</GrantID><Agency>Shandong Province Natural Science Foundation of China</Agency><Country/></Grant><Grant><GrantID>Grant No. 2019KJK004</GrantID><Agency>Support Program for Youth Innovation Technology in Colleges and Universities of Shandong Province of China</Agency><Country/></Grant><Grant><GrantID>J18KZ013</GrantID><Agency>Key Project of Shandong Province Higher Educational Science and Technology Program of China</Agency><Country/></Grant><Grant><GrantID>N/A</GrantID><Agency>The Brigham and Women's Hospital BRI Fund to Sustain Research Excellence (to X.W.)</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>02</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Cells</MedlineTA><NlmUniqueID>101600052</NlmUniqueID><ISSNLinking>2073-4409</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D035683">MicroRNAs</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D035683" MajorTopicYN="Y">MicroRNAs</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009046" MajorTopicYN="N">Motor Neurons</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="Y">Neurodegenerative Diseases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">biomarker</Keyword><Keyword MajorTopicYN="N">miRNAs</Keyword><Keyword MajorTopicYN="N">neurodegeneration</Keyword><Keyword MajorTopicYN="N">noncoding RNA</Keyword><Keyword MajorTopicYN="N">therapy</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>12</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>2</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>2</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>2</Month><Day>15</Day><Hour>1</Hour><Minute>5</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>2</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>4</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35159383</ArticleId><ArticleId IdType="pmc">PMC8833997</ArticleId><ArticleId IdType="doi">10.3390/cells11030572</ArticleId><ArticleId IdType="pii">cells11030572</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hardiman O., Al-Chalabi A., Chio A., Corr E.M., Logroscino G., Robberecht W., Shaw P.J., Simmons Z., van den Berg L.H. Amyotrophic lateral sclerosis. Nat. Rev. Dis Primers. 2017;3:17071. doi: 10.1038/nrdp.2017.71.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrdp.2017.71</ArticleId><ArticleId IdType="pubmed">28980624</ArticleId></ArticleIdList></Reference><Reference><Citation>Amado D.A., Davidson B.L. Gene therapy for ALS: A review. Mol. Ther. 2021;29:3345&#x2013;3358. doi: 10.1016/j.ymthe.2021.04.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ymthe.2021.04.008</ArticleId><ArticleId IdType="pmc">PMC8636154</ArticleId><ArticleId IdType="pubmed">33839324</ArticleId></ArticleIdList></Reference><Reference><Citation>Sebastiao A.M., Rei N., Ribeiro J.A. Amyotrophic Lateral Sclerosis (ALS) and Adenosine Receptors. Front. Pharm. 2018;9:267. doi: 10.3389/fphar.2018.00267.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2018.00267</ArticleId><ArticleId IdType="pmc">PMC5911503</ArticleId><ArticleId IdType="pubmed">29713276</ArticleId></ArticleIdList></Reference><Reference><Citation>Bucchia M., Ramirez A., Parente V., Simone C., Nizzardo M., Magri F., Dametti S., Corti S. Therapeutic development in amyotrophic lateral sclerosis. Clin. Ther. 2015;37:668&#x2013;680. doi: 10.1016/j.clinthera.2014.12.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clinthera.2014.12.020</ArticleId><ArticleId IdType="pubmed">25666449</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Chalabi A., van den Berg L.H., Veldink J. Gene discovery in amyotrophic lateral sclerosis: Implications for clinical management. Nat. Rev. Neurol. 2017;13:96&#x2013;104. doi: 10.1038/nrneurol.2016.182.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2016.182</ArticleId><ArticleId IdType="pubmed">27982040</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaiswal M.K. Riluzole and edaravone: A tale of two amyotrophic lateral sclerosis drugs. Med. Res. Rev. 2019;39:733&#x2013;748. doi: 10.1002/med.21528.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/med.21528</ArticleId><ArticleId IdType="pubmed">30101496</ArticleId></ArticleIdList></Reference><Reference><Citation>Chia R., Chi&#xf2; A., Traynor B.J. Novel genes associated with amyotrophic lateral sclerosis: Diagnostic and clinical implications. Lancet Neurol. 2018;17:94&#x2013;102. doi: 10.1016/S1474-4422(17)30401-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(17)30401-5</ArticleId><ArticleId IdType="pmc">PMC5901717</ArticleId><ArticleId IdType="pubmed">29154141</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu Y., Fotinos A., Mao L.L., Atassi N., Zhou E.W., Ahmad S., Guan Y., Berry J.D., Cudkowicz M.E., Wang X. Neuroprotective agents target molecular mechanisms of disease in ALS. Drug Discov. Today. 2015;20:65&#x2013;75. doi: 10.1016/j.drudis.2014.08.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.drudis.2014.08.016</ArticleId><ArticleId IdType="pubmed">25205348</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang X., Guan Y., Zhao Z., Meng F., Wang X., Gao X., Liu J., Chen Y., Zhou F., Zhou S., et al. Potential Roles of the WNT Signaling Pathway in Amyotrophic Lateral Sclerosis. Cells. 2021;10:839. doi: 10.3390/cells10040839.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells10040839</ArticleId><ArticleId IdType="pmc">PMC8068170</ArticleId><ArticleId IdType="pubmed">33917816</ArticleId></ArticleIdList></Reference><Reference><Citation>Lattante S., Ciura S., Rouleau G.A., Kabashi E. Defining the genetic connection linking amyotrophic lateral sclerosis (ALS) with frontotemporal dementia (FTD) Trends Genet. 2015;31:263&#x2013;273. doi: 10.1016/j.tig.2015.03.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tig.2015.03.005</ArticleId><ArticleId IdType="pubmed">25869998</ArticleId></ArticleIdList></Reference><Reference><Citation>Brenner D., Weishaupt J.H. Update on amyotrophic lateral sclerosis genetics. Curr. Opin. Neurol. 2019;32:735&#x2013;739. doi: 10.1097/WCO.0000000000000737.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/WCO.0000000000000737</ArticleId><ArticleId IdType="pubmed">31335339</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosen D.R., Siddique T., Patterson D., Figlewicz D.A., Sapp P., Hentati A., Donaldson D., Goto J., O&#x2019;Regan J.P., Deng H.X., et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature. 1993;362:59&#x2013;62. doi: 10.1038/362059a0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/362059a0</ArticleId><ArticleId IdType="pubmed">8446170</ArticleId></ArticleIdList></Reference><Reference><Citation>Karnati H.K., Panigrahi M.K., Gutti R.K., Greig N.H., Tamargo I.A. miRNAs: Key Players in Neurodegenerative Disorders and Epilepsy. J. Alzheimers Dis. 2015;48:563&#x2013;580. doi: 10.3233/JAD-150395.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-150395</ArticleId><ArticleId IdType="pmc">PMC5187980</ArticleId><ArticleId IdType="pubmed">26402105</ArticleId></ArticleIdList></Reference><Reference><Citation>Qiu L., Tan E.K., Zeng L. microRNAs and Neurodegenerative Diseases. Adv. Exp. Med. Biol. 2015;888:85&#x2013;105. doi: 10.1007/978-3-319-22671-2_6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-3-319-22671-2_6</ArticleId><ArticleId IdType="pubmed">26663180</ArticleId></ArticleIdList></Reference><Reference><Citation>Paez-Colasante X., Figueroa-Romero C., Sakowski S.A., Goutman S.A., Feldman E.L. Amyotrophic lateral sclerosis: Mechanisms and therapeutics in the epigenomic era. Nat. Rev. Neurol. 2015;11:266&#x2013;279. doi: 10.1038/nrneurol.2015.57.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2015.57</ArticleId><ArticleId IdType="pubmed">25896087</ArticleId></ArticleIdList></Reference><Reference><Citation>Mandrioli J., Mediani L., Alberti S., Carra S. ALS and FTD: Where RNA metabolism meets protein quality control. Semin Cell Dev. Biol. 2020;99:183&#x2013;192. doi: 10.1016/j.semcdb.2019.06.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.semcdb.2019.06.003</ArticleId><ArticleId IdType="pubmed">31254610</ArticleId></ArticleIdList></Reference><Reference><Citation>Mulligan V.K., Kerman A., Laister R.C., Sharda P.R., Arslan P.E., Chakrabartty A. Early steps in oxidation-induced SOD1 misfolding: Implications for non-amyloid protein aggregation in familial ALS. J. Mol. Biol. 2012;421:631&#x2013;652. doi: 10.1016/j.jmb.2012.04.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jmb.2012.04.016</ArticleId><ArticleId IdType="pubmed">22542526</ArticleId></ArticleIdList></Reference><Reference><Citation>Bose P., Armstrong G.A.B., Drapeau P. Neuromuscular junction abnormalities in a zebrafish loss-of-function model of TDP-43. J. Neurophysiol. 2019;121:285&#x2013;297. doi: 10.1152/jn.00265.2018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/jn.00265.2018</ArticleId><ArticleId IdType="pubmed">30461368</ArticleId></ArticleIdList></Reference><Reference><Citation>Beers D.R., Appel S.H. Immune dysregulation in amyotrophic lateral sclerosis: Mechanisms and emerging therapies. Lancet Neurol. 2019;18:211&#x2013;220. doi: 10.1016/S1474-4422(18)30394-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(18)30394-6</ArticleId><ArticleId IdType="pubmed">30663610</ArticleId></ArticleIdList></Reference><Reference><Citation>Chou C.C., Zhang Y., Umoh M.E., Vaughan S.W., Lorenzini I., Liu F., Sayegh M., Donlin-Asp P.G., Chen Y.H., Duong D.M., et al. TDP-43 pathology disrupts nuclear pore complexes and nucleocytoplasmic transport in ALS/FTD. Nat. Neurosci. 2018;21:228&#x2013;239. doi: 10.1038/s41593-017-0047-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-017-0047-3</ArticleId><ArticleId IdType="pmc">PMC5800968</ArticleId><ArticleId IdType="pubmed">29311743</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitra J., Hegde M.L. A Commentary on TDP-43 and DNA Damage Response in Amyotrophic Lateral Sclerosis. J. Exp. Neurosci. 2019;13:1179069519880166. doi: 10.1177/1179069519880166.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1179069519880166</ArticleId><ArticleId IdType="pmc">PMC6791036</ArticleId><ArticleId IdType="pubmed">31656396</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawahara Y., Kwak S. Excitotoxicity and ALS: What is unique about the AMPA receptors expressed on spinal motor neurons? Amyotroph. Lateral Scler. 2005;6:131&#x2013;144. doi: 10.1080/14660820510037872.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14660820510037872</ArticleId><ArticleId IdType="pubmed">16183555</ArticleId></ArticleIdList></Reference><Reference><Citation>Cozzolino M., Carri M.T. Mitochondrial dysfunction in ALS. Prog. Neurobiol. 2012;97:54&#x2013;66. doi: 10.1016/j.pneurobio.2011.06.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pneurobio.2011.06.003</ArticleId><ArticleId IdType="pubmed">21827820</ArticleId></ArticleIdList></Reference><Reference><Citation>Barber S.C., Shaw P.J. Oxidative stress in ALS: Key role in motor neuron injury and therapeutic target. Free Radic. Biol. Med. 2010;48:629&#x2013;641. doi: 10.1016/j.freeradbiomed.2009.11.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.freeradbiomed.2009.11.018</ArticleId><ArticleId IdType="pubmed">19969067</ArticleId></ArticleIdList></Reference><Reference><Citation>Theunissen F., West P.K., Brennan S., Petrovic B., Hooshmand K., Akkari P.A., Keon M., Guennewig B. New perspectives on cytoskeletal dysregulation and mitochondrial mislocalization in amyotrophic lateral sclerosis. Transl. Neurodegener. 2021;10:46. doi: 10.1186/s40035-021-00272-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40035-021-00272-z</ArticleId><ArticleId IdType="pmc">PMC8597313</ArticleId><ArticleId IdType="pubmed">34789332</ArticleId></ArticleIdList></Reference><Reference><Citation>Marinkovic P., Reuter M.S., Brill M.S., Godinho L., Kerschensteiner M., Misgeld T. Axonal transport deficits and degeneration can evolve independently in mouse models of amyotrophic lateral sclerosis. Proc. Natl. Acad. Sci. USA. 2012;109:4296&#x2013;4301. doi: 10.1073/pnas.1200658109.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1200658109</ArticleId><ArticleId IdType="pmc">PMC3306689</ArticleId><ArticleId IdType="pubmed">22371592</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu J., Wang F. Role of Neuroinflammation in Amyotrophic Lateral Sclerosis: Cellular Mechanisms and Therapeutic Implications. Front. Immunol. 2017;8:1005. doi: 10.3389/fimmu.2017.01005.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2017.01005</ArticleId><ArticleId IdType="pmc">PMC5567007</ArticleId><ArticleId IdType="pubmed">28871262</ArticleId></ArticleIdList></Reference><Reference><Citation>Raffaele S., Boccazzi M., Fumagalli M. Oligodendrocyte Dysfunction in Amyotrophic Lateral Sclerosis: Mechanisms and Therapeutic Perspectives. Cells. 2021;10:565. doi: 10.3390/cells10030565.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells10030565</ArticleId><ArticleId IdType="pmc">PMC8000560</ArticleId><ArticleId IdType="pubmed">33807572</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryan T.A., Tumbarello D.A. Optineurin: A Coordinator of Membrane-Associated Cargo Trafficking and Autophagy. Front. Immunol. 2018;9:1024. doi: 10.3389/fimmu.2018.01024.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2018.01024</ArticleId><ArticleId IdType="pmc">PMC5962687</ArticleId><ArticleId IdType="pubmed">29867991</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu T.X., Rothenberg M.E. MicroRNA. J. Allergy Clin. Immunol. 2018;141:1202&#x2013;1207. doi: 10.1016/j.jaci.2017.08.034.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaci.2017.08.034</ArticleId><ArticleId IdType="pmc">PMC5889965</ArticleId><ArticleId IdType="pubmed">29074454</ArticleId></ArticleIdList></Reference><Reference><Citation>Correia de Sousa M., Gjorgjieva M., Dolicka D., Sobolewski C., Foti M. Deciphering miRNAs&#x2019; Action through miRNA Editing. Int. J. Mol. Sci. 2019;20:6249. doi: 10.3390/ijms20246249.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms20246249</ArticleId><ArticleId IdType="pmc">PMC6941098</ArticleId><ArticleId IdType="pubmed">31835747</ArticleId></ArticleIdList></Reference><Reference><Citation>Kozomara A., Griffiths-Jones S. miRBase: Annotating high confidence microRNAs using deep sequencing data. Nucleic Acids Res. 2014;42:D68&#x2013;D73. doi: 10.1093/nar/gkt1181.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkt1181</ArticleId><ArticleId IdType="pmc">PMC3965103</ArticleId><ArticleId IdType="pubmed">24275495</ArticleId></ArticleIdList></Reference><Reference><Citation>Godlewski J., Lenart J., Salinska E. MicroRNA in Brain pathology: Neurodegeneration the Other Side of the Brain Cancer. Non-Coding RNA. 2019;5:20. doi: 10.3390/ncrna5010020.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ncrna5010020</ArticleId><ArticleId IdType="pmc">PMC6468660</ArticleId><ArticleId IdType="pubmed">30813461</ArticleId></ArticleIdList></Reference><Reference><Citation>Gascon E., Gao F.B. Cause or Effect: Misregulation of microRNA Pathways in Neurodegeneration. Front. Neurosci. 2012;6:48. doi: 10.3389/fnins.2012.00048.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2012.00048</ArticleId><ArticleId IdType="pmc">PMC3321503</ArticleId><ArticleId IdType="pubmed">22509148</ArticleId></ArticleIdList></Reference><Reference><Citation>Krol J., Loedige I., Filipowicz W. The widespread regulation of microRNA biogenesis, function and decay. Nat. Rev. Genet. 2010;11:597&#x2013;610. doi: 10.1038/nrg2843.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrg2843</ArticleId><ArticleId IdType="pubmed">20661255</ArticleId></ArticleIdList></Reference><Reference><Citation>Herranz H., Cohen S.M. MicroRNAs and gene regulatory networks: Managing the impact of noise in biological systems. Genes Dev. 2010;24:1339&#x2013;1344. doi: 10.1101/gad.1937010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/gad.1937010</ArticleId><ArticleId IdType="pmc">PMC2895193</ArticleId><ArticleId IdType="pubmed">20595229</ArticleId></ArticleIdList></Reference><Reference><Citation>Gershoni-Emek N., Altman T., Ionescu A., Costa C.J., Gradus-Pery T., Willis D.E., Perlson E. Localization of RNAi Machinery to Axonal Branch Points and Growth Cones Is Facilitated by Mitochondria and Is Disrupted in ALS. Front. Mol. Neurosci. 2018;11:311. doi: 10.3389/fnmol.2018.00311.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnmol.2018.00311</ArticleId><ArticleId IdType="pmc">PMC6134038</ArticleId><ArticleId IdType="pubmed">30233312</ArticleId></ArticleIdList></Reference><Reference><Citation>Haramati S., Chapnik E., Sztainberg Y., Eilam R., Zwang R., Gershoni N., McGlinn E., Heiser P.W., Wills A.M., Wirguin I., et al. miRNA malfunction causes spinal motor neuron disease. Proc. Natl. Acad. Sci. USA. 2010;107:13111&#x2013;13116. doi: 10.1073/pnas.1006151107.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1006151107</ArticleId><ArticleId IdType="pmc">PMC2919953</ArticleId><ArticleId IdType="pubmed">20616011</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu D., Raafat A., Pak E., Clemens S., Murashov A.K. Dicer-microRNA pathway is critical for peripheral nerve regeneration and functional recovery in vivo and regenerative axonogenesis in vitro. Exp. Neurol. 2012;233:555&#x2013;565. doi: 10.1016/j.expneurol.2011.11.041.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2011.11.041</ArticleId><ArticleId IdType="pmc">PMC3268911</ArticleId><ArticleId IdType="pubmed">22178326</ArticleId></ArticleIdList></Reference><Reference><Citation>Otaegi G., Pollock A., Sun T. An Optimized Sponge for microRNA miR-9 Affects Spinal Motor Neuron Development in vivo. Front. Neurosci. 2011;5:146. doi: 10.3389/fnins.2011.00146.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2011.00146</ArticleId><ArticleId IdType="pmc">PMC3251795</ArticleId><ArticleId IdType="pubmed">22291613</ArticleId></ArticleIdList></Reference><Reference><Citation>Gagliardi D., Comi G.P., Bresolin N., Corti S. MicroRNAs as regulators of cell death mechanisms in amyotrophic lateral sclerosis. J. Cell Mol. Med. 2019;23:1647&#x2013;1656. doi: 10.1111/jcmm.13976.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jcmm.13976</ArticleId><ArticleId IdType="pmc">PMC6378226</ArticleId><ArticleId IdType="pubmed">30614179</ArticleId></ArticleIdList></Reference><Reference><Citation>Klatt C.L., Theis V., Hahn S., Theiss C., Matschke V. Deregulated miR-29b-3p Correlates with Tissue-Specific Activation of Intrinsic Apoptosis in An Animal Model of Amyotrophic Lateral Sclerosis. Cells. 2019;8:1077. doi: 10.3390/cells8091077.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells8091077</ArticleId><ArticleId IdType="pmc">PMC6770833</ArticleId><ArticleId IdType="pubmed">31547454</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou F., Zhang C., Guan Y., Chen Y., Lu Q., Jie L., Gao H., Du H., Zhang H., Liu Y., et al. Screening the expression characteristics of several miRNAs in G93A-SOD1 transgenic mouse: Altered expression of miRNA-124 is associated with astrocyte differentiation by targeting Sox2 and Sox9. J. Neurochem. 2018;145:51&#x2013;67. doi: 10.1111/jnc.14229.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jnc.14229</ArticleId><ArticleId IdType="pubmed">28960306</ArticleId></ArticleIdList></Reference><Reference><Citation>Kye M.J., Goncalves Ido C. The role of miRNA in motor neuron disease. Front. Cell Neurosci. 2014;8:15. doi: 10.3389/fncel.2014.00015.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2014.00015</ArticleId><ArticleId IdType="pmc">PMC3906579</ArticleId><ArticleId IdType="pubmed">24523674</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh T., Yadav S. Role of microRNAs in neurodegeneration induced by environmental neurotoxicants and aging. Ageing Res. Rev. 2020;60:101068. doi: 10.1016/j.arr.2020.101068.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.arr.2020.101068</ArticleId><ArticleId IdType="pubmed">32283224</ArticleId></ArticleIdList></Reference><Reference><Citation>Ha M., Kim V.N. Regulation of microRNA biogenesis. Nat. Rev. Mol. Cell Biol. 2014;15:509&#x2013;524. doi: 10.1038/nrm3838.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrm3838</ArticleId><ArticleId IdType="pubmed">25027649</ArticleId></ArticleIdList></Reference><Reference><Citation>Michlewski G., Caceres J.F. Post-transcriptional control of miRNA biogenesis. RNA. 2019;25:1&#x2013;16. doi: 10.1261/rna.068692.118.</Citation><ArticleIdList><ArticleId IdType="doi">10.1261/rna.068692.118</ArticleId><ArticleId IdType="pmc">PMC6298569</ArticleId><ArticleId IdType="pubmed">30333195</ArticleId></ArticleIdList></Reference><Reference><Citation>Saliminejad K., Khorram Khorshid H.R., Soleymani Fard S., Ghaffari S.H. An overview of microRNAs: Biology, functions, therapeutics, and analysis methods. J. Cell Physiol. 2019;234:5451&#x2013;5465. doi: 10.1002/jcp.27486.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcp.27486</ArticleId><ArticleId IdType="pubmed">30471116</ArticleId></ArticleIdList></Reference><Reference><Citation>Pu M., Chen J., Tao Z., Miao L., Qi X., Wang Y., Ren J. Regulatory network of miRNA on its target: Coordination between transcriptional and post-transcriptional regulation of gene expression. Cell Mol. Life Sci. 2019;76:441&#x2013;451. doi: 10.1007/s00018-018-2940-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00018-018-2940-7</ArticleId><ArticleId IdType="pubmed">30374521</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen L., Heikkinen L., Wang C., Yang Y., Sun H., Wong G. Trends in the development of miRNA bioinformatics tools. Brief. Bioinform. 2019;20:1836&#x2013;1852. doi: 10.1093/bib/bby054.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bib/bby054</ArticleId><ArticleId IdType="pmc">PMC7414524</ArticleId><ArticleId IdType="pubmed">29982332</ArticleId></ArticleIdList></Reference><Reference><Citation>Carthew R.W., Sontheimer E.J. Origins and Mechanisms of miRNAs and siRNAs. Cell. 2009;136:642&#x2013;655. doi: 10.1016/j.cell.2009.01.035.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2009.01.035</ArticleId><ArticleId IdType="pmc">PMC2675692</ArticleId><ArticleId IdType="pubmed">19239886</ArticleId></ArticleIdList></Reference><Reference><Citation>Vishnoi A., Rani S. MiRNA Biogenesis and Regulation of Diseases: An Overview. Methods Mol. Biol. 2017;1509:1&#x2013;10. doi: 10.1007/978-1-4939-6524-3_1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-1-4939-6524-3_1</ArticleId><ArticleId IdType="pubmed">27826912</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang L., Zhang L. MicroRNAs in amyotrophic lateral sclerosis: From pathogenetic involvement to diagnostic biomarker and therapeutic agent development. Neurol. Sci. 2020;41:3569&#x2013;3577. doi: 10.1007/s10072-020-04773-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10072-020-04773-z</ArticleId><ArticleId IdType="pubmed">33006054</ArticleId></ArticleIdList></Reference><Reference><Citation>Goodall E.F., Heath P.R., Bandmann O., Kirby J., Shaw P.J. Neuronal dark matter: The emerging role of microRNAs in neurodegeneration. Front. Cell Neurosci. 2013;7:178. doi: 10.3389/fncel.2013.00178.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2013.00178</ArticleId><ArticleId IdType="pmc">PMC3794211</ArticleId><ArticleId IdType="pubmed">24133413</ArticleId></ArticleIdList></Reference><Reference><Citation>Juzwik C.A., Drake S.S., Zhang Y., Paradis-Isler N., Sylvester A., Amar-Zifkin A., Douglas C., Morquette B., Moore C.S., Fournier A.E. microRNA dysregulation in neurodegenerative diseases: A systematic review. Prog. Neurobiol. 2019;182:101664. doi: 10.1016/j.pneurobio.2019.101664.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pneurobio.2019.101664</ArticleId><ArticleId IdType="pubmed">31356849</ArticleId></ArticleIdList></Reference><Reference><Citation>Ravnik-Glavac M., Glavac D. Circulating RNAs as Potential Biomarkers in Amyotrophic Lateral Sclerosis. Int. J. Mol. Sci. 2020;21:1714. doi: 10.3390/ijms21051714.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms21051714</ArticleId><ArticleId IdType="pmc">PMC7084402</ArticleId><ArticleId IdType="pubmed">32138249</ArticleId></ArticleIdList></Reference><Reference><Citation>Dardiotis E., Aloizou A.M., Siokas V., Patrinos G.P., Deretzi G., Mitsias P., Aschner M., Tsatsakis A. The Role of MicroRNAs in Patients with Amyotrophic Lateral Sclerosis. J. Mol. Neurosci. 2018;66:617&#x2013;628. doi: 10.1007/s12031-018-1204-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12031-018-1204-1</ArticleId><ArticleId IdType="pubmed">30415446</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamzeiy H., Suluyayla R., Brinkrolf C., Janowski S.J., Hofest&#xe4;dt R., Allmer J. Visualization and Analysis of miRNAs Implicated in Amyotrophic Lateral Sclerosis Within Gene Regulatory Pathways. Stud. Health Technol. Inf. 2018;253:183&#x2013;187. doi: 10.3233/978-1-61499-896-9-183.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/978-1-61499-896-9-183</ArticleId><ArticleId IdType="pubmed">30147069</ArticleId></ArticleIdList></Reference><Reference><Citation>Laneve P., Tollis P., Caffarelli E. RNA Deregulation in Amyotrophic Lateral Sclerosis: The Noncoding Perspective. Int. J. Mol. Sci. 2021;22:285. doi: 10.3390/ijms221910285.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms221910285</ArticleId><ArticleId IdType="pmc">PMC8508793</ArticleId><ArticleId IdType="pubmed">34638636</ArticleId></ArticleIdList></Reference><Reference><Citation>Freischmidt A., Muller K., Zondler L., Weydt P., Volk A.E., Bozic A.L., Walter M., Bonin M., Mayer B., von Arnim C.A., et al. Serum microRNAs in patients with genetic amyotrophic lateral sclerosis and pre-manifest mutation carriers. Brain. 2014;137:2938&#x2013;2950. doi: 10.1093/brain/awu249.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awu249</ArticleId><ArticleId IdType="pubmed">25193138</ArticleId></ArticleIdList></Reference><Reference><Citation>Freischmidt A., Muller K., Zondler L., Weydt P., Mayer B., von Arnim C.A., Hubers A., Dorst J., Otto M., Holzmann K., et al. Serum microRNAs in sporadic amyotrophic lateral sclerosis. Neurobiol. Aging. 2015;36:2660.e15&#x2013;2660.e20. doi: 10.1016/j.neurobiolaging.2015.06.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2015.06.003</ArticleId><ArticleId IdType="pubmed">26142125</ArticleId></ArticleIdList></Reference><Reference><Citation>Raheja R., Regev K., Healy B.C., Mazzola M.A., Beynon V., Von Glehn F., Paul A., Diaz-Cruz C., Gholipour T., Glanz B.I., et al. Correlating serum micrornas and clinical parameters in amyotrophic lateral sclerosis. Muscle Nerve. 2018;58:261&#x2013;269. doi: 10.1002/mus.26106.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.26106</ArticleId><ArticleId IdType="pmc">PMC6103911</ArticleId><ArticleId IdType="pubmed">29466830</ArticleId></ArticleIdList></Reference><Reference><Citation>Pegoraro V., Marozzo R., Angelini C. MicroRNAs and HDAC4 protein expression in the skeletal muscle of ALS patients. Clin. Neuropathol. 2020;39:105&#x2013;114. doi: 10.5414/NP301233.</Citation><ArticleIdList><ArticleId IdType="doi">10.5414/NP301233</ArticleId><ArticleId IdType="pubmed">32000889</ArticleId></ArticleIdList></Reference><Reference><Citation>Russell A.P., Wada S., Vergani L., Hock M.B., Lamon S., Leger B., Ushida T., Cartoni R., Wadley G.D., Hespel P., et al. Disruption of skeletal muscle mitochondrial network genes and miRNAs in amyotrophic lateral sclerosis. Neurobiol. Dis. 2013;49:107&#x2013;117. doi: 10.1016/j.nbd.2012.08.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2012.08.015</ArticleId><ArticleId IdType="pubmed">22975021</ArticleId></ArticleIdList></Reference><Reference><Citation>De Felice B., Guida M., Guida M., Coppola C., De Mieri G., Cotrufo R. A miRNA signature in leukocytes from sporadic amyotrophic lateral sclerosis. Gene. 2012;508:35&#x2013;40. doi: 10.1016/j.gene.2012.07.058.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.gene.2012.07.058</ArticleId><ArticleId IdType="pubmed">22903028</ArticleId></ArticleIdList></Reference><Reference><Citation>Shioya M., Obayashi S., Tabunoki H., Arima K., Saito Y., Ishida T., Satoh J. Aberrant microRNA expression in the brains of neurodegenerative diseases: miR-29a decreased in Alzheimer disease brains targets neurone navigator 3. Neuropathol. Appl. Neurobiol. 2010;36:320&#x2013;330. doi: 10.1111/j.1365-2990.2010.01076.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2990.2010.01076.x</ArticleId><ArticleId IdType="pubmed">20202123</ArticleId></ArticleIdList></Reference><Reference><Citation>Vrabec K., Bostjancic E., Koritnik B., Leonardis L., Dolenc Groselj L., Zidar J., Rogelj B., Glavac D., Ravnik-Glavac M. Differential Expression of Several miRNAs and the Host Genes AATK and DNM2 in Leukocytes of Sporadic ALS Patients. Front. Mol. Neurosci. 2018;11:106. doi: 10.3389/fnmol.2018.00106.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnmol.2018.00106</ArticleId><ArticleId IdType="pmc">PMC5893848</ArticleId><ArticleId IdType="pubmed">29670510</ArticleId></ArticleIdList></Reference><Reference><Citation>Joilin G., Leigh P.N., Newbury S.F., Hafezparast M. An Overview of MicroRNAs as Biomarkers of ALS. Front. Neurol. 2019;10:186. doi: 10.3389/fneur.2019.00186.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2019.00186</ArticleId><ArticleId IdType="pmc">PMC6416171</ArticleId><ArticleId IdType="pubmed">30899244</ArticleId></ArticleIdList></Reference><Reference><Citation>Gomes C., Cunha C., Nascimento F., Ribeiro J.A., Vaz A.R., Brites D. Cortical Neurotoxic Astrocytes with Early ALS Pathology and miR-146a Deficit Replicate Gliosis Markers of Symptomatic SOD1G93A Mouse Model. Mol. Neurobiol. 2019;56:2137&#x2013;2158. doi: 10.1007/s12035-018-1220-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-018-1220-8</ArticleId><ArticleId IdType="pubmed">29995256</ArticleId></ArticleIdList></Reference><Reference><Citation>Gomes C., Sequeira C., Barbosa M., Cunha C., Vaz A.R., Brites D. Astrocyte regional diversity in ALS includes distinct aberrant phenotypes with common and causal pathological processes. Exp. Cell Res. 2020;395:112209. doi: 10.1016/j.yexcr.2020.112209.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.yexcr.2020.112209</ArticleId><ArticleId IdType="pubmed">32739211</ArticleId></ArticleIdList></Reference><Reference><Citation>Barbosa M., Gomes C., Sequeira C., Goncalves-Ribeiro J., Pina C.C., Carvalho L.A., Moreira R., Vaz S.H., Vaz A.R., Brites D. Recovery of Depleted miR-146a in ALS Cortical Astrocytes Reverts Cell Aberrancies and Prevents Paracrine Pathogenicity on Microglia and Motor Neurons. Front. Cell Dev. Biol. 2021;9:634355. doi: 10.3389/fcell.2021.634355.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcell.2021.634355</ArticleId><ArticleId IdType="pmc">PMC8103001</ArticleId><ArticleId IdType="pubmed">33968923</ArticleId></ArticleIdList></Reference><Reference><Citation>Sison S.L., Patitucci T.N., Seminary E.R., Villalon E., Lorson C.L., Ebert A.D. Astrocyte-produced miR-146a as a mediator of motor neuron loss in spinal muscular atrophy. Hum. Mol. Genet. 2017;26:3409&#x2013;3420. doi: 10.1093/hmg/ddx230.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddx230</ArticleId><ArticleId IdType="pubmed">28637335</ArticleId></ArticleIdList></Reference><Reference><Citation>Parisi C., Arisi I., D&#x2019;Ambrosi N., Storti A.E., Brandi R., D&#x2019;Onofrio M., Volonte C. Dysregulated microRNAs in amyotrophic lateral sclerosis microglia modulate genes linked to neuroinflammation. Cell Death Dis. 2013;4:e959. doi: 10.1038/cddis.2013.491.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/cddis.2013.491</ArticleId><ArticleId IdType="pmc">PMC3877562</ArticleId><ArticleId IdType="pubmed">24336079</ArticleId></ArticleIdList></Reference><Reference><Citation>Peplow P., Martinez B. MicroRNA expression in animal models of amyotrophic lateral sclerosis and potential therapeutic approaches. Neural Regen. Res. 2022;17:728. doi: 10.4103/1673-5374.322431.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/1673-5374.322431</ArticleId><ArticleId IdType="pmc">PMC8530133</ArticleId><ArticleId IdType="pubmed">34472458</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams A.H., Valdez G., Moresi V., Qi X., McAnally J., Elliott J.L., Bassel-Duby R., Sanes J.R., Olson E.N. MicroRNA-206 delays ALS progression and promotes regeneration of neuromuscular synapses in mice. Science. 2009;326:1549&#x2013;1554. doi: 10.1126/science.1181046.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1181046</ArticleId><ArticleId IdType="pmc">PMC2796560</ArticleId><ArticleId IdType="pubmed">20007902</ArticleId></ArticleIdList></Reference><Reference><Citation>de Andrade H.M., de Albuquerque M., Avansini S.H., de S.R.C., Dogini D.B., Nucci A., Carvalho B., Lopes-Cendes I., Franca M.C., Jr. MicroRNAs-424 and 206 are potential prognostic markers in spinal onset amyotrophic lateral sclerosis. J. Neurol. Sci. 2016;368:19&#x2013;24. doi: 10.1016/j.jns.2016.06.046.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2016.06.046</ArticleId><ArticleId IdType="pubmed">27538595</ArticleId></ArticleIdList></Reference><Reference><Citation>Waller R., Goodall E.F., Milo M., Cooper-Knock J., Da Costa M., Hobson E., Kazoka M., Wollff H., Heath P.R., Shaw P.J., et al. Serum miRNAs miR-206, 143&#x2013;3p and 374b-5p as potential biomarkers for amyotrophic lateral sclerosis (ALS) Neurobiol. Aging. 2017;55:123&#x2013;131. doi: 10.1016/j.neurobiolaging.2017.03.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2017.03.027</ArticleId><ArticleId IdType="pmc">PMC5455071</ArticleId><ArticleId IdType="pubmed">28454844</ArticleId></ArticleIdList></Reference><Reference><Citation>Cunha C., Santos C., Gomes C., Fernandes A., Correia A.M., Sebastiao A.M., Vaz A.R., Brites D. Downregulated Glia Interplay and Increased miRNA-155 as Promising Markers to Track ALS at an Early Stage. Mol. Neurobiol. 2018;55:4207&#x2013;4224. doi: 10.1007/s12035-017-0631-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-017-0631-2</ArticleId><ArticleId IdType="pubmed">28612258</ArticleId></ArticleIdList></Reference><Reference><Citation>Koval E.D., Shaner C., Zhang P., du Maine X., Fischer K., Tay J., Chau B.N., Wu G.F., Miller T.M. Method for widespread microRNA-155 inhibition prolongs survival in ALS-model mice. Hum. Mol. Genet. 2013;22:4127&#x2013;4135. doi: 10.1093/hmg/ddt261.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddt261</ArticleId><ArticleId IdType="pmc">PMC3781640</ArticleId><ArticleId IdType="pubmed">23740943</ArticleId></ArticleIdList></Reference><Reference><Citation>Butovsky O., Jedrychowski M.P., Cialic R., Krasemann S., Murugaiyan G., Fanek Z., Greco D.J., Wu P.M., Doykan C.E., Kiner O., et al. Targeting miR-155 restores abnormal microglia and attenuates disease in SOD1 mice. Ann. Neurol. 2015;77:75&#x2013;99. doi: 10.1002/ana.24304.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.24304</ArticleId><ArticleId IdType="pmc">PMC4432483</ArticleId><ArticleId IdType="pubmed">25381879</ArticleId></ArticleIdList></Reference><Reference><Citation>Parisi C., Napoli G., Amadio S., Spalloni A., Apolloni S., Longone P., Volonte C. MicroRNA-125b regulates microglia activation and motor neuron death in ALS. Cell Death Differ. 2016;23:531&#x2013;541. doi: 10.1038/cdd.2015.153.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/cdd.2015.153</ArticleId><ArticleId IdType="pmc">PMC5072447</ArticleId><ArticleId IdType="pubmed">26794445</ArticleId></ArticleIdList></Reference><Reference><Citation>Li C., Chen Y., Chen X., Wei Q., Cao B., Shang H. Downregulation of MicroRNA-193b-3p Promotes Autophagy and Cell Survival by Targeting TSC1/mTOR Signaling in NSC-34 Cells. Front. Mol. Neurosci. 2017;10:160. doi: 10.3389/fnmol.2017.00160.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnmol.2017.00160</ArticleId><ArticleId IdType="pmc">PMC5447700</ArticleId><ArticleId IdType="pubmed">28611587</ArticleId></ArticleIdList></Reference><Reference><Citation>Rohm M., May C., Marcus K., Steinbach S., Theis V., Theiss C., Matschke V. The microRNA miR-375-3p and the Tumor Suppressor NDRG2 are Involved in Sporadic Amyotrophic Lateral Sclerosis. Cell Physiol. Biochem. 2019;52:1412&#x2013;1426. doi: 10.33594/000000099.</Citation><ArticleIdList><ArticleId IdType="doi">10.33594/000000099</ArticleId><ArticleId IdType="pubmed">31075191</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim K.Y., Kim Y.R., Choi K.W., Lee M., Lee S., Im W., Shin J.Y., Kim J.Y., Hong Y.H., Kim M., et al. Downregulated miR-18b-5p triggers apoptosis by inhibition of calcium signaling and neuronal cell differentiation in transgenic SOD1 (G93A) mice and SOD1 (G17S and G86S) ALS patients. Transl. Neurodegener. 2020;9:23. doi: 10.1186/s40035-020-00203-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40035-020-00203-4</ArticleId><ArticleId IdType="pmc">PMC7328278</ArticleId><ArticleId IdType="pubmed">32605607</ArticleId></ArticleIdList></Reference><Reference><Citation>Li C., Chen Y., Chen X., Wei Q., Ou R., Gu X., Cao B., Shang H. MicroRNA-183-5p is stress-inducible and protects neurons against cell death in amyotrophic lateral sclerosis. J. Cell Mol. Med. 2020;24:8614&#x2013;8622. doi: 10.1111/jcmm.15490.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jcmm.15490</ArticleId><ArticleId IdType="pmc">PMC7412410</ArticleId><ArticleId IdType="pubmed">32558113</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaz A.R., Vizinha D., Morais H., Colaco A.R., Loch-Neckel G., Barbosa M., Brites D. Overexpression of miR-124 in Motor Neurons Plays a Key Role in ALS Pathological Processes. Int. J. Mol. Sci. 2021;22:6128. doi: 10.3390/ijms22116128.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22116128</ArticleId><ArticleId IdType="pmc">PMC8201298</ArticleId><ArticleId IdType="pubmed">34200161</ArticleId></ArticleIdList></Reference><Reference><Citation>Hawley Z.C.E., Campos-Melo D., Strong M.J. MiR-105 and miR-9 regulate the mRNA stability of neuronal intermediate filaments. Implications for the pathogenesis of amyotrophic lateral sclerosis (ALS) Brain Res. 2019;1706:93&#x2013;100. doi: 10.1016/j.brainres.2018.10.032.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2018.10.032</ArticleId><ArticleId IdType="pubmed">30385300</ArticleId></ArticleIdList></Reference><Reference><Citation>Moloney E.B., de Winter F., Verhaagen J. ALS as a distal axonopathy: Molecular mechanisms affecting neuromuscular junction stability in the presymptomatic stages of the disease. Front. Neurosci. 2014;8:252. doi: 10.3389/fnins.2014.00252.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2014.00252</ArticleId><ArticleId IdType="pmc">PMC4132373</ArticleId><ArticleId IdType="pubmed">25177267</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Harten A.C.M., Phatnani H., Przedborski S. Non-cell-autonomous pathogenic mechanisms in amyotrophic lateral sclerosis. Trends Neurosci. 2021;44:658&#x2013;668. doi: 10.1016/j.tins.2021.04.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tins.2021.04.008</ArticleId><ArticleId IdType="pubmed">34006386</ArticleId></ArticleIdList></Reference><Reference><Citation>Maimon R., Ionescu A., Bonnie A., Sweetat S., Wald-Altman S., Inbar S., Gradus T., Trotti D., Weil M., Behar O., et al. miR126-5p Downregulation Facilitates Axon Degeneration and NMJ Disruption via a Non-Cell-Autonomous Mechanism in ALS. J. Neurosci. 2018;38:5478&#x2013;5494. doi: 10.1523/JNEUROSCI.3037-17.2018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.3037-17.2018</ArticleId><ArticleId IdType="pmc">PMC6001038</ArticleId><ArticleId IdType="pubmed">29773756</ArticleId></ArticleIdList></Reference><Reference><Citation>Helferich A.M., Brockmann S.J., Reinders J., Deshpande D., Holzmann K., Brenner D., Andersen P.M., Petri S., Thal D.R., Michaelis J., et al. Dysregulation of a novel miR-1825/TBCB/TUBA4A pathway in sporadic and familial ALS. Cell Mol. Life Sci. 2018;75:4301&#x2013;4319. doi: 10.1007/s00018-018-2873-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00018-018-2873-1</ArticleId><ArticleId IdType="pubmed">30030593</ArticleId></ArticleIdList></Reference><Reference><Citation>Wahid F., Khan T., Kim Y.Y. MicroRNA and diseases: Therapeutic potential as new generation of drugs. Biochimie. 2014;104:12&#x2013;26. doi: 10.1016/j.biochi.2014.05.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biochi.2014.05.004</ArticleId><ArticleId IdType="pubmed">24859535</ArticleId></ArticleIdList></Reference><Reference><Citation>Akbari Dilmaghani N., Hussen B.M., Nateghinia S., Taheri M., Ghafouri-Fard S. Emerging role of microRNAs in the pathogenesis of amyotrophic lateral sclerosis. Metab. Brain Dis. 2021;36:737&#x2013;749. doi: 10.1007/s11011-021-00697-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11011-021-00697-5</ArticleId><ArticleId IdType="pubmed">33604874</ArticleId></ArticleIdList></Reference><Reference><Citation>Bai Z., Wei J., Yu C., Han X., Qin X., Zhang C., Liao W., Li L., Huang W. Non-viral nanocarriers for intracellular delivery of microRNA therapeutics. J. Mater. Chem. B. 2019;7:1209&#x2013;1225. doi: 10.1039/C8TB02946F.</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/C8TB02946F</ArticleId><ArticleId IdType="pubmed">32255160</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller T., Cudkowicz M., Shaw P.J., Andersen P.M., Atassi N., Bucelli R.C., Genge A., Glass J., Ladha S., Ludolph A.L., et al. Phase 1-2 Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS. N. Engl. J. Med. 2020;383:109&#x2013;119. doi: 10.1056/NEJMoa2003715.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2003715</ArticleId><ArticleId IdType="pubmed">32640130</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaj T., Ojala D.S., Ekman F.K., Byrne L.C., Limsirichai P., Schaffer D.V. In vivo genome editing improves motor function and extends survival in a mouse model of ALS. Sci. Adv. 2017;3:eaar3952. doi: 10.1126/sciadv.aar3952.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciadv.aar3952</ArticleId><ArticleId IdType="pmc">PMC5738228</ArticleId><ArticleId IdType="pubmed">29279867</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim C.K.W., Gapinske M., Brooks A.K., Woods W.S., Powell J.E., Zeballos C.M., Winter J., Perez-Pinera P., Gaj T. Treatment of a Mouse Model of ALS by In Vivo Base Editing. Mol. Ther. 2020;28:1177&#x2013;1189. doi: 10.1016/j.ymthe.2020.01.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ymthe.2020.01.005</ArticleId><ArticleId IdType="pmc">PMC7132599</ArticleId><ArticleId IdType="pubmed">31991108</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang N. An overview of viral and nonviral delivery systems for microRNA. Int J. Pharm. Investig. 2015;5 doi: 10.4103/2230-973X.167646.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/2230-973X.167646</ArticleId><ArticleId IdType="pmc">PMC4674998</ArticleId><ArticleId IdType="pubmed">26682187</ArticleId></ArticleIdList></Reference><Reference><Citation>Aigner A. Cellular delivery in vivo of siRNA-based therapeutics. Curr. Pharm. Des. 2008;14:3603&#x2013;3619. doi: 10.2174/138161208786898815.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/138161208786898815</ArticleId><ArticleId IdType="pubmed">19075737</ArticleId></ArticleIdList></Reference><Reference><Citation>van Zundert B., Brown R.H., Jr. Silencing strategies for therapy of SOD1-mediated ALS. Neurosci. Lett. 2017;636:32&#x2013;39. doi: 10.1016/j.neulet.2016.07.059.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neulet.2016.07.059</ArticleId><ArticleId IdType="pubmed">27507699</ArticleId></ArticleIdList></Reference><Reference><Citation>Nolan K., Mitchem M.R., Jimenez-Mateos E.M., Henshall D.C., Concannon C.G., Prehn J.H. Increased expression of microRNA-29a in ALS mice: Functional analysis of its inhibition. J. Mol. Neurosci. 2014;53:231&#x2013;241. doi: 10.1007/s12031-014-0290-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12031-014-0290-y</ArticleId><ArticleId IdType="pubmed">24696165</ArticleId></ArticleIdList></Reference><Reference><Citation>Zerah M., Piguet F., Colle M.A., Raoul S., Deschamps J.Y., Deniaud J., Gautier B., Toulgoat F., Bieche I., Laurendeau I., et al. Intracerebral Gene Therapy Using AAVrh.10-hARSA Recombinant Vector to Treat Patients with Early-Onset Forms of Metachromatic Leukodystrophy: Preclinical Feasibility and Safety Assessments in Nonhuman Primates. Hum. Gene Ther. Clin. Dev. 2015;26:113&#x2013;124. doi: 10.1089/humc.2014.139.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/humc.2014.139</ArticleId><ArticleId IdType="pubmed">25758611</ArticleId></ArticleIdList></Reference><Reference><Citation>Borel F., Gernoux G., Cardozo B., Metterville J.P., Toro Cabrera G.C., Song L., Su Q., Gao G.P., Elmallah M.K., Brown R.H., Jr., et al. Therapeutic rAAVrh10 Mediated SOD1 Silencing in Adult SOD1(G93A) Mice and Nonhuman Primates. Hum. Gene Ther. 2016;27:19&#x2013;31. doi: 10.1089/hum.2015.122.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/hum.2015.122</ArticleId><ArticleId IdType="pmc">PMC4741242</ArticleId><ArticleId IdType="pubmed">26710998</ArticleId></ArticleIdList></Reference><Reference><Citation>Stoica L., Todeasa S.H., Cabrera G.T., Salameh J.S., ElMallah M.K., Mueller C., Brown R.H., Jr., Sena-Esteves M. AAV delivered artificial microRNA extends survival and delays paralysis in an Amyotrophic Lateral Sclerosis mouse model. Ann. Neurol. 2016;79:687&#x2013;700. doi: 10.1002/ana.24618.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.24618</ArticleId><ArticleId IdType="pmc">PMC5374859</ArticleId><ArticleId IdType="pubmed">26891182</ArticleId></ArticleIdList></Reference><Reference><Citation>Li D., Liu C., Yang C., Wang D., Wu D., Qi Y., Su Q., Gao G., Xu Z., Guo Y. Slow Intrathecal Injection of rAAVrh10 Enhances its Transduction of Spinal Cord and Therapeutic Efficacy in a Mutant SOD1 Model of ALS. Neuroscience. 2017;365:192&#x2013;205. doi: 10.1016/j.neuroscience.2017.10.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroscience.2017.10.001</ArticleId><ArticleId IdType="pmc">PMC5757625</ArticleId><ArticleId IdType="pubmed">29024785</ArticleId></ArticleIdList></Reference><Reference><Citation>Tung Y.T., Lu Y.L., Peng K.C., Yen Y.P., Chang M., Li J., Jung H., Thams S., Huang Y.P., Hung J.H., et al. Mir-17 approximately 92 Governs Motor Neuron Subtype Survival by Mediating Nuclear PTEN. Cell Rep. 2015;11:1305&#x2013;1318. doi: 10.1016/j.celrep.2015.04.050.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2015.04.050</ArticleId><ArticleId IdType="pubmed">26004179</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanning K.C., Kaplan A., Henderson C.E. Motor neuron diversity in development and disease. Annu. Rev. Neurosci. 2010;33:409&#x2013;440. doi: 10.1146/annurev.neuro.051508.135722.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.neuro.051508.135722</ArticleId><ArticleId IdType="pubmed">20367447</ArticleId></ArticleIdList></Reference><Reference><Citation>Swinnen B., Robberecht W. The phenotypic variability of amyotrophic lateral sclerosis. Nat. Rev. Neurol. 2014;10:661&#x2013;670. doi: 10.1038/nrneurol.2014.184.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2014.184</ArticleId><ArticleId IdType="pubmed">25311585</ArticleId></ArticleIdList></Reference><Reference><Citation>Tung Y.T., Peng K.C., Chen Y.C., Yen Y.P., Chang M., Thams S., Chen J.A. Mir-17~92 Confers Motor Neuron Subtype Differential Resistance to ALS-Associated Degeneration. Cell Stem Cell. 2019;25:193&#x2013;209.e197. doi: 10.1016/j.stem.2019.04.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.stem.2019.04.016</ArticleId><ArticleId IdType="pubmed">31155482</ArticleId></ArticleIdList></Reference><Reference><Citation>Martier R., Liefhebber J.M., Garcia-Osta A., Miniarikova J., Cuadrado-Tejedor M., Espelosin M., Ursua S., Petry H., van Deventer S.J., Evers M.M., et al. Targeting RNA-Mediated Toxicity in C9orf72 ALS and/or FTD by RNAi-Based Gene Therapy. Mol. Ther. Nucleic Acids. 2019;16:26&#x2013;37. doi: 10.1016/j.omtn.2019.02.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.omtn.2019.02.001</ArticleId><ArticleId IdType="pmc">PMC6393708</ArticleId><ArticleId IdType="pubmed">30825670</ArticleId></ArticleIdList></Reference><Reference><Citation>Lind L.A., Andel E.M., McCall A.L., Dhindsa J.S., Johnson K.A., Stricklin O.E., Mueller C., ElMallah M.K., Lever T.E., Nichols N.L. Intralingual Administration of AAVrh10-miR(SOD1) Improves Respiratory But Not Swallowing Function in a Superoxide Dismutase-1 Mouse Model of Amyotrophic Lateral Sclerosis. Hum. Gene Ther. 2020;31:828&#x2013;838. doi: 10.1089/hum.2020.065.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/hum.2020.065</ArticleId><ArticleId IdType="pmc">PMC7462029</ArticleId><ArticleId IdType="pubmed">32498636</ArticleId></ArticleIdList></Reference><Reference><Citation>Mueller C., Berry J.D., McKenna-Yasek D.M., Gernoux G., Owegi M.A., Pothier L.M., Douthwright C.L., Gelevski D., Luppino S.D., Blackwood M., et al. SOD1 Suppression with Adeno-Associated Virus and MicroRNA in Familial ALS. N. Engl. J. Med. 2020;383:151&#x2013;158. doi: 10.1056/NEJMoa2005056.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2005056</ArticleId><ArticleId IdType="pubmed">32640133</ArticleId></ArticleIdList></Reference><Reference><Citation>Musaro A. Understanding ALS: New therapeutic approaches. FEBS J. 2013;280:4315&#x2013;4322. doi: 10.1111/febs.12087.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/febs.12087</ArticleId><ArticleId IdType="pubmed">23217177</ArticleId></ArticleIdList></Reference><Reference><Citation>Worringer K.A., Rand T.A., Hayashi Y., Sami S., Takahashi K., Tanabe K., Narita M., Srivastava D., Yamanaka S. The let-7/LIN-41 pathway regulates reprogramming to human induced pluripotent stem cells by controlling expression of prodifferentiation genes. Cell Stem Cell. 2014;14:40&#x2013;52. doi: 10.1016/j.stem.2013.11.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.stem.2013.11.001</ArticleId><ArticleId IdType="pmc">PMC3982312</ArticleId><ArticleId IdType="pubmed">24239284</ArticleId></ArticleIdList></Reference><Reference><Citation>Bajan S., Hutvagner G. RNA-Based Therapeutics: From Antisense Oligonucleotides to miRNAs. Cells. 2020;9:137. doi: 10.3390/cells9010137.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells9010137</ArticleId><ArticleId IdType="pmc">PMC7016530</ArticleId><ArticleId IdType="pubmed">31936122</ArticleId></ArticleIdList></Reference><Reference><Citation>Foust K.D., Salazar D.L., Likhite S., Ferraiuolo L., Ditsworth D., Ilieva H., Meyer K., Schmelzer L., Braun L., Cleveland D.W., et al. Therapeutic AAV9-mediated suppression of mutant SOD1 slows disease progression and extends survival in models of inherited ALS. Mol. Ther. 2013;21:2148&#x2013;2159. doi: 10.1038/mt.2013.211.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mt.2013.211</ArticleId><ArticleId IdType="pmc">PMC3863799</ArticleId><ArticleId IdType="pubmed">24008656</ArticleId></ArticleIdList></Reference><Reference><Citation>Sudhakar V., Richardson R.M. Gene Therapy for Neurodegenerative Diseases. Neurotherapeutics. 2019;16:166&#x2013;175. doi: 10.1007/s13311-018-00694-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13311-018-00694-0</ArticleId><ArticleId IdType="pmc">PMC6361055</ArticleId><ArticleId IdType="pubmed">30542906</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>